Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

Implantation Mycoses in Immunocompromised Patients: a retrospective review of disease course and treatment efficacy

Clinical Trial Details

The primary objective of this retrospective review is to assess the disease course of implantation mycoses in immunocompromised patients when compared to patients without immunocompromise. The secondary objective is to assess demographic factors associated with patients with this diagnosis within our patient population.

Implantation mycoses (also known as deep fungal infections) are one of the four classifications of fungal infections: superficial, cutaneous, subcutaneous, and deep. Of the four classifications, deep infections are most challenging to treat in that they involve disseminated disease that can affect the lungs, brain, spleen, liver, kidneys, and more. The array of patients that can be affected by these mycoses continues to expand. One patient sub-population in particular, those with immunocompromise, are at higher risk of contracting deep fungal infections and have a difficult time fighting them. This study aims to report demographics, comorbidities, treatments, medications, disease course, reinfection rates, and more of both immunocompromised patients and controls.

Deep fungal infections are particularly difficult to treat in healthy patients, and that challenge only toughens in patients with immunocompromise. Through this retrospective review, we hope to elucidate treatment modalities that shorten disease course in all patients, especially those with immunocompromise who may also be at risk for other opportunistic infections.


Study Visits & Compensation:
No visits will be conducted, and patients will not be compensated. The project will utilize review of patient charts from Epic EMR.

Key Eligibility: 

1. Males and females over the age of 18
2. A clinical diagnosis of an implantation mycosis (chromoblastomycosis, eumycetoma, sporotrichosis, murocmycosis)

Study contact by location

Upper East Side - Manhattan

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:

23-06026109

Status

Open to Enrollment